By Bhanvi Satija

(Reuters) -More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday.

The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United States for treating type 2 diabetes. They are sold as Zepbound and Wegovy, respectively, for weight loss and are being tested for other conditions.

Use of the injectable drugs was highest among adults with diabetes aged 50–64 at 33.3%, reflecting the more significant disease burden in this group, the report said.

A quarter or 25.3% of adults with diabetes aged 18 to 34 reported using a GLP-1 drug, while the adoption rate was 20.8% among those

See Full Page